Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) insider Jennifer Tousignant sold 2,272 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Viridian Therapeutics Price Performance

VRDN stock traded down $0.44 on Friday, reaching $30.68. The company had a trading volume of 1,083,635 shares, compared to its average volume of 1,383,215. The company’s fifty day moving average is $29.56 and its 200 day moving average is $22.24. The company has a market cap of $2.93 billion, a P/E ratio of -10.16 and a beta of 0.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $34.04.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.48. Viridian Therapeutics had a negative return on equity of 78.50% and a negative net margin of 426.58%.The company had revenue of $70.57 million during the quarter, compared to the consensus estimate of $16.21 million. The business’s revenue was up 81993.0% compared to the same quarter last year. On average, research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analyst Weigh In

VRDN has been the topic of a number of recent research reports. Truist Financial set a $41.00 target price on shares of Viridian Therapeutics in a report on Monday, November 24th. Wedbush boosted their price objective on shares of Viridian Therapeutics from $42.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Royal Bank Of Canada boosted their price objective on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wall Street Zen upgraded shares of Viridian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Oppenheimer lifted their target price on shares of Viridian Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.75.

Institutional Investors Weigh In On Viridian Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Invesco Ltd. increased its position in Viridian Therapeutics by 44.3% during the first quarter. Invesco Ltd. now owns 47,771 shares of the company’s stock worth $644,000 after purchasing an additional 14,672 shares during the last quarter. Raymond James Financial Inc. grew its stake in shares of Viridian Therapeutics by 1.4% during the 1st quarter. Raymond James Financial Inc. now owns 318,240 shares of the company’s stock valued at $4,290,000 after buying an additional 4,453 shares during the period. Northern Trust Corp grew its stake in shares of Viridian Therapeutics by 1.2% during the 1st quarter. Northern Trust Corp now owns 702,517 shares of the company’s stock valued at $9,470,000 after buying an additional 8,375 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after buying an additional 876 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Viridian Therapeutics by 33.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.